When was Plaquetec founded?

Plaquetec was founded in 2008 and raised its 1st funding round 16 years after it was founded.

Where is Plaquetec located?

Plaquetec is headquartered in Cambridge, United Kingdom.

Which legal entities is Plaquetec associated with?

Plaquetec is associated with Plaquetec Limited.

How many employees does Plaquetec have?

As of Apr 30, 2026, the latest employee count at Plaquetec is 4.

Is Plaquetec a funded company?

Plaquetec is a funded company, having raised a total of $13M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 30, 2024.

When was the latest funding round of Plaquetec?

Plaquetec's latest funding was a $***** Series A round on Apr 27, 2026, with participation from 0 investor. Its primary sector is Genomics. In United Kingdom, the Genomics sector has seen $66.7M in funding in 2026 to date.

Where does Plaquetec rank among its competitors?

Plaquetec ranks 15th amongst 94 active competitors, of which 32 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Plaquetec, which secured $5M in Apr, 2026.

Who are the top competitors of Plaquetec?

Plaquetec's top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Plaquetec secured the most recent funding round in April, 2026.

Plaquetec - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.

Website: www.plaquetec.com/
Email ID: *****@plaquetec.com

Key Metrics

Founded Year

2008

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$13M in 2 rounds

Latest Funding Round

Series A, Apr 27, 2026, $*****

Investors

Future Fund & 23 more

Ranked

15^th among 94 active competitors

Employee Count

4 as on Apr 30, 2026

Similar Companies

Seer & 120 more

View Plaquetec's full profile

Plaquetec is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Plaquetec Limited CIN: 6212970 , Germany, Active	Apr 15, 2007	-	2 (As on Jan 31, 2022)

Plaquetec has raised a total funding of $13M over 2 rounds. Its first funding round was on Apr 30, 2024. Plaquetec has 3 institutional investors and 21 angel investors.

Here is the list of recent funding rounds of Plaquetec:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 27, 2026	3177851	Series A	2578549	1381992	8172994	7076901
Apr 30, 2024	4728110	Series A	6605020	9627401	Future Fund	2858263

Access funding benchmarks and valuations. Sign up today!

View details of Plaquetec's funding rounds and investors

Plaquetec's Board of Directors

Plaquetec's board has 3 active members. Christopher John Latimer Haynes, Martin Gordon Robert Stapleton and Simon Williams are independent board members.

Here is the list of Plaquetec's board of directors:

Name	Type	Representing	Status	Duration
Christopher John Latimer Haynes	Independent board member	-	Current	19y 1m
wntavjq	Independent board member	-	Current	4y 7m
zfnohoe	Independent board member	-	Current	1y 1m

Plaquetec's employee count trend

Plaquetec has 4 employees as of Apr 26. Here is Plaquetec's employee count trend over the years:

Uncover Plaquetec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Plaquetec include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of Plaquetec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 7 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Deep Track Capital, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, BCM Technologies & 3 others	64/100
7th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Eos Advisory, Mercia & 35 others	62/100
8th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	CICC, Guangzhou Yuexiu Industrial Investment Fund Management ... & 12 others	56/100
9th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
15th	Plaquetec 2008, Cambridge (United Kingdom), Series A	Developer of a method to profile the biology of coronary artery	$13M	Future Fund, Ipex Capital & 22 others	50/100